Clinical Trial Update: Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial comparing imatinib or nilotinib with pegylated interferon-α2b in chronic myeloid leukemia; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib (imatinib)
• Nilotinib (nilotinib)
• Pegylated Interferon α-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2023-01-25